Beta Cat Pharmaceuticals, Inc.
Novel biopharmaceutical therapeutics discovered through proprietary drug discovery platforms
- Sector
- Biotech
- Headquarters
- HOUSTON, TX
- Founded
- 2014
- Latest Form D
- $2.6M, Jun 2018
- Total capital
- $5.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $5.5M
- 4 Form D · last Jun 2018
- 100 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 2 pending · first 2017
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$2.6M
- Private capital raisedForm D · SEC · 3rd filing$1.4M
- Private capital raisedForm D · SEC · 2nd filing$1M
- Private capital raisedForm D · SEC · 1st filing$500K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alain C CappelutiExecutive OfficerNamed in SEC Form D filings
- Casey P. CunninghamExecutive OfficerNamed in SEC Form D filings
- James EadieDirectorNamed in SEC Form D filings
- Joe CunninghamDirectorNamed in SEC Form D filings
- Jonathan P NorthrupExecutive Officer, DirectorNamed in SEC Form D filings
- Joseph P. CunninghamDirectorNamed in SEC Form D filings
Show all 12 people
- Kenneth CarterDirectorNamed in SEC Form D filings
- Rahul ArasExecutive OfficerNamed in SEC Form D filings
- Scott JordanExecutive Officer, DirectorNamed in SEC Form D filings
- Stephen P. HorriganExecutive OfficerNamed in SEC Form D filings
- Sunil C SharmaExecutive Officer, DirectorNamed in SEC Form D filings
- Uma BhattExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 5- GrantedMethods For Treatment Of Fibrotic DiseasesUSPTOUS 11,298,346
- GrantedANTHRACENE-9, 10-DIONE Dioxime Compound Prodrugs And Their UsesUSPTOUS 9,963,475
- GrantedANTHRACENE-9, 10-DIONE Dioxime Compound Prodrugs And Their UsesUSPTOUS 9,725,473
Show all 5 patent records
- Methods For Treatment Of Fibrotic DiseasesApr 12, 2022 · US 11,298,346Granted
- ANTHRACENE-9, 10-DIONE Dioxime Compound Prodrugs And Their UsesMay 8, 2018 · US 9,963,475Granted
- ANTHRACENE-9, 10-DIONE Dioxime Compound Prodrugs And Their UsesAug 8, 2017 · US 9,725,473Granted
- Formulations Of Tegavivint And Related CompoundsApplication 62679404Pending
- ANTHRACENE-9, 10-DIONE Dioxime Compounds Prodrugs And Their UsesApplication PCTUS2016044506Pending
Related companies, and why
- Replicate Bioscience, Inc.Similar federal contract value in Biotech · null in contracts
- Amicrobe, Inc.Similar federal contract value in Biotech · null in contracts
- NurExone Biologic Inc.Similar federal contract value in Biotech · null in contracts
- Outpost Medicine, LLCSimilar federal contract value in Biotech · null in contracts
- AI Proteins, Inc.Similar federal contract value in Biotech · null in contracts
- FibroGenSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .